Skip to content
Screener

Total Equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$20.25B+17.9%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Achieve Life Sciences logo
Achieve Life SciencesACHV
$10.68M+3.9%
Septerna, Inc. logo
Septerna, Inc.SEPN
$386.72M+2.4%
RFL
Rafael Holdings, Inc.RFL
$75.39M-6.4%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$451.84M-3.8%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$203.46M-77.0%
Enterprise value$147.55M-82.7%

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by Sionna Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 7:17 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033876
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; no shares issued or outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 45,075,651 and 44,723,585 shares issued, 45,075,651 and 44,723,585 shares outstanding as of March 31, 2026 and December 31, 2025, respectively4545
Additional paid-in capital571,380562,602
Accumulated other comprehensive (loss) income(84)540
Accumulated deficit(283,133)(256,354)
Total stockholders’ equity288,208306,833
Total liabilities and stockholders’ equity$305,039$325,953

Item 1. Financial Statements

FAQ

What is Sionna Therapeutics's total equity?
Sionna Therapeutics (SION) reported total equity of $288.21M in Q1 2026.
How has Sionna Therapeutics's total equity changed year-over-year?
Sionna Therapeutics's total equity decreased by 18.1% year-over-year, from $351.77M to $288.21M.
What is the long-term trend for Sionna Therapeutics's total equity?
Over 2 years (2023 to 2025), Sionna Therapeutics's total equity has grown at a 63.4% compound annual growth rate (CAGR), from -$114.88M to $306.83M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Sionna Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude